Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (41-50 of 153) with videos related to

Pageof 16
Sort By:
Blood|February 28, 2002
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemiaMichele Baccarani, Gianantonio Rosti, Antonio de Vivo, et al.
Cells|July 14, 2023
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel InsightsMiriam Iezza, Sofia Cortesi, Emanuela Ottaviani, et al.
Plos One|July 7, 2015
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid LeukemiaManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Frontiers in Oncology|August 22, 2022
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitorsManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2019
Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignanciesKathrin Sommer, Francesco Cottone, Neil K Aaronson, et al.
Leukemia|November 25, 2023
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND studyGianantonio Rosti, Tim H Brümmendorf, Björn T Gjertsen, et al.
Oncotarget|April 14, 2017
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapySimona Luatti, Carmen Baldazzi, Giulia Marzocchi, et al.
Leukemia Research|June 2, 2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinibMassimo Breccia, Francesca Palandri, Anna Paola Iori, et al.
Pageof 16

Showing results (41-50 of 153) with videos related to

Sort By:
Pageof 16
Blood|February 28, 2002
A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemiaMichele Baccarani, Gianantonio Rosti, Antonio de Vivo, et al.
Cells|July 14, 2023
Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel InsightsMiriam Iezza, Sofia Cortesi, Emanuela Ottaviani, et al.
Plos One|July 7, 2015
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid LeukemiaManuela Mancini, Elisa Leo, Ken-Ichi Takemaru, et al.
Frontiers in Oncology|August 22, 2022
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitorsManuela Mancini, Sara De Santis, Cecilia Monaldi, et al.
Blood|May 4, 2011
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS scoreJoerg Hasford, Michele Baccarani, Verena Hoffmann, et al.
Leukemia Research|July 19, 2011
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinibSimona Soverini, Alessandra Gnani, Caterina De Benedittis, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 30, 2019
Consistency matters: measurement invariance of the EORTC QLQ-C30 questionnaire in patients with hematologic malignanciesKathrin Sommer, Francesco Cottone, Neil K Aaronson, et al.
Leukemia|November 25, 2023
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND studyGianantonio Rosti, Tim H Brümmendorf, Björn T Gjertsen, et al.
Oncotarget|April 14, 2017
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapySimona Luatti, Carmen Baldazzi, Giulia Marzocchi, et al.
Leukemia Research|June 2, 2009
Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinibMassimo Breccia, Francesca Palandri, Anna Paola Iori, et al.
Pageof 16